Comparison · NCT04524273-d3713efc
Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Overall: Inebilizumab 300 mg vs Overall: Placebo: Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population. Trial comparisons, record NCT04524273-d3713efc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04524273-d3713efc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.6 | 0.499 | 0.693 | wilson | |
| Risk in group 2 | 0.67 | 0.569 | 0.758 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0703 | -0.204 | 0.0674 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.895 | 0.719 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | 0.738 | 0.405 | 1.34 | log | |
| Number needed to treat, for one fewer participant with the outcome on Overall: Inebilizumab 300 mg than on Overall: Placebo | 14.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Overall: Inebilizumab 300 mg | All participants received inebilizumab IV on Days 1 and 15. Participants with Anti-AChR-Ab+ also received inebilizumab IV on Day 183 (Week 26). | 57 | 95 | OG001 |
| Group 2 | Overall: Placebo | All participants received placebo IV on Days 1 and 15. Participants with Anti-AChR-Ab+ also received placebo IV on Day 183 (Week 26). | 61 | 91 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population
- Description
- Outcome measure is reported for the overall population.
- Time frame
- Week 26
- Population
FAS: all participants randomized who received at least one dose of IP in the study and had baseline and at least one post-baseline observations.~Outcome Measure refers to participants with baseline steroids\> 5 mg.
Source ClinicalTrials.gov
Trial
- Title
- Myasthenia Gravis Inebilizumab Trial
- NCT number
- NCT04524273
- Phases
- PHASE3
- Conditions
- Myasthenia Gravis
- Interventions
- inebilizumab, IV Placebo
- Lead sponsor
- Amgen
- Results first posted
- 2026-03-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04524273?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04524273-d3713efc